Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 30 versus MYDAYIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 30 versus MYDAYIS.
ADDERALL XR 30 vs MYDAYIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR is a central nervous system (CNS) stimulant. It contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, leading to increased synaptic concentrations. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully understood but is thought to involve activation of dopaminergic and noradrenergic pathways in the prefrontal cortex.
MYDAYIS is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action in ADHD is not fully elucidated, but they block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase their release into the extraneuronal space.
20-60 mg orally once daily in the morning; start at 20 mg once daily, titrate by 10 mg weekly based on tolerability and response.
Oral, 12.5 mg or 25 mg once daily in the morning.
None Documented
None Documented
The terminal elimination half-life is 10–13 hours for dextroamphetamine (the more active enantiomer) in adults; for the racemic mixture (dextroamphetamine/amphetamine), the half-life is shorter (6–8 hours) due to differential metabolism. Clinical context: Steady-state achieved within 2–3 days; once-daily dosing is sufficient.
12 hours for d-methylphenidate; 3-4 hours for l-methylphenidate; clinical context: d-isomer provides extended coverage; l-isomer contributes minimal activity
Renal: approximately 90% (30–40% unchanged, remainder as metabolites including dehydroamphetamine and hydroxylated metabolites). Fecal: <4%. Biliary: minimal.
Renal (approx. 90% as unchanged drug and 10% as inactive metabolites); fecal <5%
Category C
Category C
CNS Stimulant
CNS Stimulant